166 related articles for article (PubMed ID: 25970452)
1. Drug development: Mix and match.
Scudellari M
Nature; 2015 May; 521(7551):S12-4. PubMed ID: 25970452
[No Abstract] [Full Text] [Related]
2. Novel Wnt signaling and other pathway inhibitors in the colorectal cancer genomic landscape era.
Roukos DH; Ziogas DE; Papaloukas C; Baltogiannis G
Future Oncol; 2012 Nov; 8(11):1373-6. PubMed ID: 23148609
[No Abstract] [Full Text] [Related]
3. [Mutational analysis of KRAS prior to targeted therapy in colorectal cancer. Quality control of molecular pathological methods in Sweden].
Enlund F; Helenius G; Palmqvist R; Edsjö A; Sundström M
Lakartidningen; 2010 Feb 3-9; 107(5):255-9. PubMed ID: 20297566
[No Abstract] [Full Text] [Related]
4. Challenges ahead for companion diagnostics.
Schmidt C
J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
[No Abstract] [Full Text] [Related]
5. [Progress of targeted therapy related to K-ras mutation].
Li ZW; Liu YQ
Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857
[No Abstract] [Full Text] [Related]
6. Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
Bhushan S; McLeod H; Walko CM
Clin Colorectal Cancer; 2009 Jan; 8(1):15-21. PubMed ID: 19203892
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
Chang MH; Lee IK; Si Y; Lee KS; Woo IS; Byun JH
Cancer Chemother Pharmacol; 2011 Aug; 68(2):317-23. PubMed ID: 20972872
[TBL] [Abstract][Full Text] [Related]
8. Targeted treatments in colorectal cancer: state of the art and future perspectives.
Arnold D; Seufferlein T
Gut; 2010 Jun; 59(6):838-58. PubMed ID: 20551469
[TBL] [Abstract][Full Text] [Related]
9. [Pathologic diagnosis of colorectal cancer in the era of personalized therapy].
Lai M
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):73-6. PubMed ID: 24742564
[No Abstract] [Full Text] [Related]
10. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
Song L; Li Y; He B; Gong Y
Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
[TBL] [Abstract][Full Text] [Related]
11. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
Tang R; Wang JY; Fan CW; Tsao KC; Chen HH; Wu CM; Chen JS; Changchien CR; Hsieh LL
Cancer Lett; 2004 Jul; 210(1):101-9. PubMed ID: 15172127
[TBL] [Abstract][Full Text] [Related]
12. Are we ready to restrict EGFR therapy to quadruple-negative colorectal cancer?
Hawkes E; Cunningham D
Lancet Oncol; 2010 Nov; 11(11):1020-1. PubMed ID: 21051017
[No Abstract] [Full Text] [Related]
13. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292).
Wadler S; Bajaj R; Neuberg D; Agarwal V; Haynes H; Benson AB
Cancer J Sci Am; 1997; 3(5):284-8. PubMed ID: 9327152
[TBL] [Abstract][Full Text] [Related]
14. Molecular markers of chemotherapy in advanced colorectal cancer: back to square one.
Sobrero A
Eur J Cancer; 2009 Jul; 45(11):1902-3. PubMed ID: 19502051
[No Abstract] [Full Text] [Related]
15. Immunotherapy of Colorectal Cancer.
Jäger D; Halama N; Zörnig I; Klug P; Krauss J; Haag GM
Oncol Res Treat; 2016; 39(6):346-50. PubMed ID: 27259331
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of Gene Mutations in Colorectal Cancer: Implications for Treatment.
Dienstmann R; Tabernero J
Cancer J; 2016; 22(3):149-55. PubMed ID: 27341591
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacoeconomics of molecular target drug: K-ras testing and cetuximab for colorectal cancer as an example].
Shiroiwa T; Tsutani K
Nihon Rinsho; 2012 Nov; 70 Suppl 8():664-8. PubMed ID: 23513919
[No Abstract] [Full Text] [Related]
18. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
19. Individualized therapy for metastatic colorectal cancer.
Silvestri A; Pin E; Huijbers A; Pellicani R; Parasido EM; Pierobon M; Petricoin E; Liotta L; Belluco C
J Intern Med; 2013 Jul; 274(1):1-24. PubMed ID: 23527888
[TBL] [Abstract][Full Text] [Related]
20. KRAS mutations: analytical considerations.
Herreros-Villanueva M; Chen CC; Yuan SS; Liu TC; Er TK
Clin Chim Acta; 2014 Apr; 431():211-20. PubMed ID: 24534449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
